In a phase I/II trial nivolumab, another PD-1 inhibitor, was investigated as monotherapy in terms of safety and anti-tumor activity in children and young adults with recurrent or refractory tumors including ES [100]. The gene discussed is PDCD1; the disease is Ewing sarcoma.